clinical trial · NCT05797168
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Ovarian CancerLung AdenocarcinomaEndometrial CancerLung Squamous Cell CarcinomaTorvutatug samrotecanSaruparibBevacizumabCarboplatinPalacaparibPembrolizumab
brief summary
This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors
started
Jun 5, 2023
primary completion
Aug 4, 2028
completion
Aug 4, 2028
last updated
Jul 23, 2026
detailed description
This study is a Phase I/IIa modular, open-label, multi-center study of AZD5335 administered either as monotherapy or in combination with other anti-cancer agents in participants with advanced solid malignancies
official title
A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol